
Medicare and Medicaid will not cover weight loss drugs, Trump administration decides
The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover
weight loss drugs
, the Centers for Medicare and Medicaid Services said
in a filing
published Friday by the agency.
A CMS spokesperson said the agency now believes that finalizing the proposal "is not appropriate at this time."
"CMS may consider future policy options for AOMs pending further review of both the potential benefits of these drugs including updated clinical indications, and relevant costs including fiscal impacts on stakeholders such as state Medicaid agencies," Catherine Howden, the spokesperson, said in an email.
Medicare already covers drugs that are also widely used for weight loss, like Ozempic and Mounjaro, when they are prescribed by doctors for other reasons like managing diabetes.
But under the statute governing Medicare and Medicaid, the federal government is generally banned from covering drugs "when used for weight loss."
Under the Biden administration, CMS had
proposed
to reinterpret this statute, bypassing the Congressional ban on coverage of weight loss drugs for obese, but not overweight, patients.
Since
obesity
is now widely agreed to be a disease, the Biden administration had said, treatment of that disease should be covered by Medicare's Part D prescription drug benefit.
They pointed to other situations when these kinds of drugs are allowed to be covered, like when weight change is caused by AIDS.
Expanding coverage of anti-obesity medications this way would also affect state Medicaid plans, officials said, since they are governed by the same law.
"CMS' revised interpretation would recognize obesity to be a chronic disease based on changes in medical consensus," the agency had said
last year
.
The proposal was expected to be costly for the federal government.
The Congressional Budget Office had
previously estimated
that expanding Medicare coverage to anti-obesity medications could add up to $35 billion over the next decade, even after factoring in expected savings from improved health of beneficiaries.
Medicaid programs would also have shouldered billions more in costs to cover the medications, Biden administration officials acknowledged, split between the federal government and states.
"States are also feeling substantial state budget pressure and we are doing our part to make sure patients, Medicaid enrollees all across the country can get access," Dan Tsai, the agency's top Medicaid official under the Biden administration, had told reporters.
Top advisers to Health and Human Services Secretary Robert F. Kennedy Jr., who now oversees CMS, among the nation's federal health agencies, had criticized the Biden-era move.
Healthcare entrepreneur Calley Means, now a special government employee under Kennedy,
had called it
a "betrayal of any American who cares about" the
Make America Healthy Again
movement's principles.
"Americans did NOT vote for mass injections in this election. They voted for a shift to ROOT CAUSE interventions and benefit flexibility," Means said in a
post on X
at the time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success, NVO is developing several next-generation candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. CagriSema met the primary endpoint of statistically significant weight loss in two late-stage studies. The company is already planning its regulatory submission in 2026. Novo Nordisk is also developing an early-stage candidate, Amycretin, a unimolecular GLP-1 and amylin receptor agonist, which had outperformed Wegovy in a phase I study. Novo Nordisk has also been pursuing licensing deals and acquisitions to further expand its obesity pipeline. In 2023, it acquired Inversago Pharmaceuticals, which added a small-molecule oral CB1 inverse agonist, monlunabant, to its pipeline. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, type II diabetes (T2D) and other cardiometabolic diseases. Eli Lilly LLY is NVO's fierce competitor in the obesity space, which markets its tirzepatide medicines as Mounjaro for T2D and Zepbound for obesity. Like NVO, LLY is also evaluating several next-generation weight loss candidates. Lilly recently reported first phase III success of its oral GLP-1 candidate, orforglipron, which showed significant weight reduction potential in the late-stage study. Regulatory filings for orforglipron are planned in 2025 and 2026. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. VKTX initiated a mid-stage study on the oral formulation of the candidate earlier this year and is on track to start the late-stage study on the subcutaneous version soon. Year to date, Novo Nordisk shares have plunged 15.5% compared with the industry's decline of 2.3%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading above its 50-day moving average, but below its 200-day moving average. Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 17.37 forward earnings, which is higher than 14.95 for the industry. However, the stock is trading much below its five-year mean of 29.25. Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.80 to $3.84 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.60 to $4.64. Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.56% for the large drugmaker industry, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research


New York Post
an hour ago
- New York Post
Doctors warn about ‘very real risks' of Ozempic ‘golden dosing' trend: ‘Recipes for disaster'
GLP-1 users might be jabbing for weight loss, but many are trying to combat cash loss by squeezing an extra dose out of their medication. The trend, dubbed 'golden dosing,' has been hyped by social media users as a way to get more bang for your buck. But doctors are warning it could be dangerous — and even set back your weight loss goals. 'Using a medication outside of its prescribed method is always risky — and in this case, especially unnecessary,' Dr. Michael Snyder, medical director of Bariatric Surgery at Rose Medical Center and an in-house expert at FuturHealth, told The Post. Advertisement 4 Surveys show that roughly 1 in 8 US adults have tried GLP-1 drugs. millaf – What is golden dosing? GLP-1 drugs like Ozempic, Mounjaro and Wegovy come in injectable pens that contain four doses, with each device lasting about a month. But some users have noticed that their pens often have leftover liquid after their final jab. This extra medication isn't a mistake. It's designed to allow for an initial flow check and to ensure that each of the four doses is accurate and complete. Advertisement Nevertheless, some TikTok users are extracting this leftover liquid with syringes and needles, using it as a fifth and final 'golden dose.' With out of pockets costs for these drugs sometimes topping $1,000 a pen, pulling out the extra medication has become a way to cut back a bit on exorbitant costs. But experts say the trend raises some major red flags. 'The 'golden dose' is more of a cost-saving strategy than one focused on safety and effectiveness,' Dr. Shiara Melissa Ortiz-Pujols, a bariatric surgeon at Northwell Health, told The Post. Advertisement 4 Typically, GLP-1 pens contain four doses. Fernanda – A dose of confusion GLP-1 pens deliver pre-measured doses that are carefully prescribed by healthcare providers based on factors like weight and health status. 'Any deviation — even what might seem like a 'small' one — can disrupt how your body responds,' Snyder warned. Advertisement GLP-1s are typically titrated, meaning the dosage is gradually increased over time to help the body adjust to the drug. 'As we increase the dose, we expect greater effectiveness, but we also face a higher risk of severe side effects,' Ortiz-Pujols explained. 4 Taking too much of the medication can lead to painful gastrointestinal effects. – Increasing your dose too quickly or taking inconsistent amounts week to week can worsen side effects, she said. It could also complicate your treatment plan, making it difficult for doctors to accurately track how your body is responding to the medications and make informed adjustments based on your personal needs, Snyder cautioned. From hack to hazard Attempting to recover leftover medication using a syringe also carries 'very real risks' for your health, Snyder said. Even minor miscalculations can lead to overdoses, triggering symptoms like nausea, vomiting and even pancreatitis. Advertisement 4 There's a major risk for bacterial growth if the syringe isn't completely sterile. Jo Panuwat D – On the flip side, underdosing can blunt the drug's effectiveness, resulting in weight regain and glucose instability. 'To put it simply, how comfortable would you feel using what you think is the 'right amount' of a blood pressure medication, a blood thinner, or a narcotic?' Snyder posed. 'All of those could be recipes for disaster. This situation is no different.' A hidden danger Advertisement The trend also poses a serious risk of infection. 'GLP-1 pens are designed to be used as a sealed system,' Snyder said. 'Using an external syringe breaks sterility, exposing the medication to bacteria during handling — even from clean-looking surfaces or hands.' This can lead to local infections at the injection site or even systemic infections, Snyder noted, emphasizing that the risk is particularly high for those who reuse syringes or directly touch the drug solution. 'There's no reliable way to make this DIY method safe,' Snyder said. 'That's why these pens are single-use and designed for highly controlled administration.'


Politico
an hour ago
- Politico
Dr. Jay in the hot seat
Presented by Driving the day WHAT TO DO WITH NIH'S UNSPENT FUNDS — President Donald Trump's cuts to ideologically disfavored research have left the National Institutes of Health with unspent funds. Director Jay Bhattacharya, under pressure from critics on Capitol Hill and in the research community, is pledging to change that. 'The biomedical research enterprise is being refocused and that's what will keep America at the forefront of global science, safety, and innovation,' HHS spokesperson Andrew Nixon said in a statement. The administration, Nixon confirmed, has targeted research Trump opposes on issues like transgender health care and health disparities among people of different races. Whether critics are satisfied in the end will depend not only on whether Bhattacharya follows through on his promise, but also on how he decides to spend the money. Thus far, neither he nor anyone in the Trump administration have laid out a detailed plan. By the numbers: A New York Times analysis found that the NIH had spent about $1.6 billion less between the time Trump took office Jan. 20 and the end of April compared to the same period the year before. Bhattacharya told advocates for research last month that he'd spend all of the agency's $48 billion budget for this year by the end of September. In the hot seat: Democrats will get a chance to ask Bhattacharya for more details when he testifies before a Senate Appropriations subcommittee this morning. Thus far, they've focused more on the cuts than on where the money will go, reflecting their view that Trump and his Department of Government Efficiency wanted to slash government spending, not target that spending on different priorities. Trump's budget proposal, released last month, suggested as much with its call for a 40 percent reduction in the NIH's total budget. The NIH is putting $500 million into a universal vaccine, which will target multiple strains of a virus. It also recently solicited proposals for autism research, with $50 million on offer. Last month, when Bhattacharya's boss, Health and Human Services Secretary Robert F. Kennedy Jr., testified before a House Appropriations subcommittee, ranking Democrat Rosa DeLauro of Connecticut pressed him: 'Are you planning to break the law by impounding congressionally appropriated funds?' Kennedy said no: 'If Congress appropriates me the money, I'm going to spend the money.' WELCOME TO TUESDAY PULSE. I'm Robert King, POLITICO's CMS reporter, filling in for Kelly today. It will be a busy week for health policy wonks as we wait for more news on whether the Senate makes changes to Medicaid in the 'big beautiful bill.' If you have any tips or news, don't hesitate to shoot me a message. Send tips, scoops and general thoughts to rking@ and khooper@ Follow along @rking_19 and @Kelhoops. AROUND THE AGENCIES RFK'S BOLDEST VACCINE STEP YET — HHS Secretary Robert F. Kennedy Jr. made his most dramatic move yet to overhaul vaccine approvals, firing all 17 members of the panel that advises the Centers for Disease Control and Prevention on vaccines. Kennedy said in an opinion piece for The Wall Street Journal that the Advisory Committee on Immunization Practices is rife with conflicts of interest and has acted as a rubber stamp for vaccines. This is the latest step for Kennedy, who has questioned the safety and effectiveness of vaccines, in changing how vaccines are approved and recommended by the federal government. He said in the op-ed that his goal is to restore faith in vaccines. It will now be up to Kennedy to pick new members to serve four-year terms on the panel, which votes on updates to CDC's vaccine schedule. The CDC director can override the recommendation but rarely does. His decision appears to contradict a promise he made to Sen. Bill Cassidy (R-La.) to secure the senator's vote for confirmation. Kennedy had promised to maintain ACIP 'without changes,' according to a speech Cassidy made on the Senate floor announcing his support for the nomination. Cassidy responded to the firings, writing on X that 'now the fear is that ACIP will be filled up with people who know nothing about vaccines except suspicion.' He added that he spoke with Kennedy and will continue to speak with him 'to ensure this is not the case.' Cassidy — who chairs the Senate Health, Education, Labor and Pensions Committee — later told reporters that the assurance he got from Kennedy was on the ACIP process rather than who sits on the panel. Sen. Susan Collins (R-Maine), who voted for Kennedy and sits on HELP, was taken by surprise. 'I don't know who serves on those committees, but it seems to be excessive to ask for everybody's resignations,' she told reporters. Congress TRYING TO STOP MEDICAID CUTS — More than 700 nursing home and assisted living professionals are heading to Capitol Hill this week to push lawmakers to avoid cuts to Medicaid in Republicans' megabill. The nursing home trade group American Health Care Association and National Center for Assisted Living will hold its annual congressional briefing this week. The fly-in day coincides with the last chance for advocates to push lawmakers for changes to the megabill. The group released a survey Monday of 363 nursing homes that found 79 percent were extremely concerned about Medicaid cuts. Another 55 percent would have to reduce their Medicaid patient population. One of the issues is a moratorium on provider taxes. A state can levy a tax on hospitals or other providers to pay for its share of Medicaid, which it jointly funds with the federal government. Under Medicaid, a state can get a higher payment from the federal government if it devotes more of its own resources. A state can use its provider tax revenue to get a higher federal payment and can replace the taxed amount from hospitals or nursing homes through a higher payment rate. The moratorium placed in the megabill, which passed the House last month, enables current provider taxes to continue but freezes any new rates. House Republicans have argued the taxes are a loophole that enable states to get more federal money, but the AHCA argued they are vital to keep nursing homes afloat. 'Restricting provider taxes is restricting resources to seniors and their caregivers,' said Clif Porter, president and CEO of the AHCA, in a statement. White House MCDONALDS, PEPSI HEAD TO WHITE HOUSE — The White House invited nearly 50 food industry and farm groups as well as major companies mentioned in a controversial report on how to Make America Health Again to meet with officials, POLITICO's Grace Yarrow reports. The list of invitees for the series of meetings includes lobbying heavyweights such as the National Cattlemen's Beef Association and American Farm Bureau Federation. Other invitees include soda brands Coca-Cola and Pepsi, as well as fast food representatives McDonald's and Yum! Brands, which own Taco Bell, KFC and others. The meetings are expected to take place this week and next. A May report from the MAHA Commission bashed farm groups for pesticide use. HHS has also called for a ban on sodas in federal nutrition programs. 'We're all very interested to see how these meetings play out over the next week and if it is a meaningful gesture or not,' said one agriculture industry insider. 'Is this just an exercise in placating stakeholders?' WHAT WE'RE READING The Washington Post reports on why Texas is spending millions to research an illegal psychedelic to jumpstart clinical trials. POLITICO's Benjamin Guggenheim reports on how Senate Finance Chair Mike Crapo is maneuvering behind closed doors to get his party's massive bill through the chamber. KFF Health News reports on when cannabis users age their health risks appear to grow.